Skip to main content

Advertisement

SpringerLink
Log in

Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Objectives Maintenance therapy is a standard therapeutic strategy in non-squamous non-small-cell lung cancer. However, there is no consensus regarding the benefit of maintenance therapy for patients with squamous cell lung cancer. We assessed maintenance therapy with S-1, an oral fluoropyrimidine agent, following induction therapy with carboplatin and S-1 in patients with squamous cell lung cancer. Methods In this phase II trial, chemotherapy-naïve patients with squamous cell lung cancer were enrolled to induction therapy with four cycles of carboplatin (at an area under the curve of 5 on day 1) and S-1 (80 mg/m2/day on days 1–14) in a 28-day cycle. Patients who achieved disease control after induction therapy received maintenance therapy with S-1 in a 21-day cycle until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival after administration of maintenance therapy. Results Fifty-one patients were enrolled in the study. The median progression-free survival from the start of maintenance therapy was 3.0 months (95 % confidence interval, 2.5–3.5). The most common toxicities associated with maintenance therapy were anemia, thrombocytopenia, and fatigue, but they were not severe. Conclusion S-1 maintenance therapy might be a feasible treatment option in patients with squamous cell lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

AUC:

area under the curve

CI:

confidence interval

ECOG:

Eastern Cooperative Oncology Group

NSCLC:

non-small-cell lung cancer

PFS:

progression-free survival

RECIST:

Response Evaluation Criteria in Solid Tumors

UMIN:

University Hospital Medical Information Network

References

  1. Fitzmaurice C, Dicker D, et al. (2013) The global burden of cancer. JAMA Oncol 1:505–527

    Google Scholar 

  2. Sawabata N, Asamura H, Goya T, Mori M, Nakanishi Y, Eguchi K, Koshiishi Y, Okumura M, Miyaoka E, Fujii Y (2012) Japanese lung cancer registry study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 5:1369–1375

    Article  Google Scholar 

  3. Meza R, Meernik C, Jeon J, Cote ML (2015) Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One 10(3):e0121323

    Article  PubMed  PubMed Central  Google Scholar 

  4. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191

    Article  CAS  PubMed  Google Scholar 

  5. Oliver TG, Patel J, Akerley W (2015) Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol 38:220–226

    Article  CAS  PubMed  Google Scholar 

  6. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14:253–263

    Article  CAS  PubMed  Google Scholar 

  7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  CAS  PubMed  Google Scholar 

  8. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923

    Article  CAS  PubMed  Google Scholar 

  9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study G (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  Google Scholar 

  10. Owonikoko TK, Ramalingam SS, Belani CP (2010) Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res 16:2496–2504

    Article  CAS  PubMed  Google Scholar 

  11. Azzoli CG, Temin S, Aliff T, Baker, S Jr., , Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2011) 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831

    Article  PubMed  PubMed Central  Google Scholar 

  12. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S, Group EGW (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii27–iii39

    Article  PubMed  Google Scholar 

  13. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432–1440

    Article  CAS  PubMed  Google Scholar 

  14. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247–255

    Article  CAS  PubMed  Google Scholar 

  15. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G, investigators S (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529

    Article  CAS  PubMed  Google Scholar 

  16. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H (2004) S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10:7860–7864

    Article  CAS  PubMed  Google Scholar 

  17. Shiroyama T, Komuta K, Imamura F, Hirashima T, Kijima T, Tachibana I, Kawase I (2011) Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer 74:85–88

    PubMed  Google Scholar 

  18. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a West Japan oncology group study. J Clin Oncol 28:5240–5246

    Article  CAS  PubMed  Google Scholar 

  19. Wada M, Yamamoto M, Ryuge S, Nagashima Y, Hayashi N, Maki S, Otani S, Katono K, Takakura A, Yanaihara T, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Masuda N (2012) Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69:1005–1011

    Article  CAS  PubMed  Google Scholar 

  20. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251

    Article  CAS  PubMed  Google Scholar 

  21. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 7:548–557

    Article  CAS  PubMed  Google Scholar 

  22. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S (2003) Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89:816–820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551

    Article  CAS  PubMed  Google Scholar 

  24. Takiuchi H, Kawabe S, Gotoh M, Katsu K (2007) Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res 1:171–176

    PubMed  PubMed Central  Google Scholar 

  25. Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S, Tokyo Cooperative Oncology G (2015) A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 26:1401–1408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K (2013) Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan oncology group LETS study. Ann Oncol 24:1326–1331

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No financial support was provided for this study.

Author information

Authors and Affiliations

  1. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan

    Seiichiro Suzuki, Masato Karayama, Naoki Inui, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura & Takafumi Suda

  2. Department of Clinical Oncology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan

    Masato Karayama

  3. Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan

    Naoki Inui & Hiroshi Watanabe

  4. Department of Respiratory Medicine, Ensyu Hospital, 1-1-1 Chuou, Hamamatsu, 430-0929, Japan

    Shigeki Kuroishi

  5. Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, 8-2 Otemachi, Shizuoka, 420-0853, Japan

    Hiroyuki Matsuda

  6. Department of Respiratory Medicine, Seirei Mikatahara General Hospital, 3453 Mikatahara-cho, Hamamatsu, 433-8558, Japan

    Koshi Yokomura

  7. Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, 426-8677, Japan

    Naoki Koshimizu

  8. Department of Respiratory Medicine, Hamamatsu Rosai Hospital, 25 Shougen-cho, Hamamatsu, 430-8525, Japan

    Mikio Toyoshima

  9. Department of Respiratory Medicine, Iwata City Hospital, 513-2 Ohkubo, Iwata, 438-8550, Japan

    Shiro Imokawa

  10. Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-ando, Shizuoka, 420-0881, Japan

    Kazuhiro Asada

  11. Department of Respiratory Medicine, City Shimuzu Hospital, 1231 Miyakami, Shizuoka, Shizuoka, 424-8636, Japan

    Masafumi Masuda

  12. Department of Respiratory Medicine, City Shizuoka Hospital, 10-93 Ote-cho, Shizuoka, Shizuoka, 420-8630, Japan

    Takashi Yamada

Authors
  1. Seiichiro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masato Karayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Inui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoyuki Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noriyuki Enomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yutaro Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shigeki Kuroishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koshi Yokomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoki Koshimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mikio Toyoshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shiro Imokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuhiro Asada
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masafumi Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Takashi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hiroshi Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Takafumi Suda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoki Inui.

Ethics declarations

Conflict of interest

All authors declare no actual or potential conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, S., Karayama, M., Inui, N. et al. Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer. Invest New Drugs 34, 490–496 (2016). https://doi.org/10.1007/s10637-016-0365-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-016-0365-4

Keywords

Search

Navigation